IDO1 and brain neoplasm: Within pediatric brain tumors, a phase I study of the oral IDO1 inhibitor, indoximod, identified a R2PD dose in pediatric patients with progressive high grade brain tumors and demonstrated safety when given concurrently with radiotherapy and temozolomide in newly diagnosed DIPG (NCT02502708) (128).